SELECTED PUBLICATIONS


  1. Tyndale RF, Sellers EM. Opioids: The Painful Public Health Reality. Clinical Pharmacology & Therapeutics. 2018;103(6):924-35.
  2. Sellers EM, Romach MK, Leiderman DB. Studies with psychedelic drugs in human volunteers. Neuropharmacology. 2018;142:116-34.
  3. Sellers EM, Romach MK. Categorization of Abuse Potential–Related Adverse Events. Clinical pharmacology in drug development. 2018;7(6):569-74.
  4. Sellers EM, Leiderman DB. Psychedelic drugs as therapeutics: No illusions about the challenges. Clinical Pharmacology & Therapeutics. 2018;103(4):561-4.
  5. Sellers EM. Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 2 Optimizing the Design of Human Abuse Potential Studies. Journal of clinical psychopharmacology. 2018;38(2):113-8.
  6. Sellers EM. Improving the Clinical Pharmacologic Assessment of Abuse Potential: Part 1 Regulatory Context and Risk Management. Journal of clinical psychopharmacology. 2018;38(1):11-8.
  7. Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy & Behavior. 2018;88:162-71.
  8. Schoedel KA, Stockis A, Sellers EM. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users. Epilepsy & Behavior. 2018;78:194-201.
  9. Schoedel K, Etges T, Levy-Cooperman N, Mills C, Sellers E, Setnik B, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the abuse potential of purified cannabidiol (CBD) in subjects with a history of recreational polydrug use (P1. 266). Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology; 2018.
  10. Mendell J, Cooperman N, Sellers E, Vince B, Kelsh D, Lee J, et al., editors. Abuse potential of mirogabalin in recreational polydrugusers. Clinical pharmacology & therapeutics; 2018: Wiley 111 river St, Hoboken 07030-5774, NJ, USA
  11. Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. Journal of psychopharmacology. 2018;32(12):1351-61.
  12. Romach MK, Rutka JT. Building Healthcare Capacity in Neurosurgery and Psychiatry in a Post-Soviet System: Ukraine. World neurosurg. 2017 Dec 8. pii: S1878-8750 (17)32111-3. Doi: 10.1016/j.wneu.2017.11.178. [Epub ahead of print)
  13. Sellers EM. Deconstructing designer drugs. Clinical Pharmacology & Therapeutics. 2017;101(2):167-9.
  14. Sellers E. Psilocybin: good trip or bad trip. Clinical Pharmacology & Therapeutics. 2017;102(4):580-4.
  15. Schoedel KA, Andreas J-O, Doty P, Eckhardt K, Sellers EM. Randomized, Double-Blind, Placebo-and Active Comparator–Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users. Journal of clinical psychopharmacology. 2017;37(6):675-83.
  16. Schoedel K, Stockis A, Sellers E. Evaluation of abuse potential of brivaracetam in healthy recreational CNS depressant users (P6. 243). Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology; 2017.
  17. Kopecky EA, Fleming AB, Levy‐Cooperman N, O'connor M, M. Sellers E. Oral human abuse potential of oxycodone DETERx®(Xtampza® ER). The Journal of Clinical Pharmacology. 2017;57(4):500-12.
  18. Coplan P, Chilcoat H, Butler S, Sellers E, Kadakia A, Harikrishnan V, et al. The Effect of an Abuse-Deterrent Opioid Formulation (OxyContin) on Opioid Abuse-Related Outcomes in the Postmarketing Setting (vol 100, pg 275, 2016). CLINICAL PHARMACOLOGY & THERAPEUTICS. 2017;101(4):541-.
  19. Carter LP, Sellers E, Henningfield J, Wang G, Lu Y, Kelsh D, et al. Evaluation of human abuse liability of JZP-110. Drug and alcohol dependence. 2017;100(171):e36.
  20. Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, et al. Assessment of the abuse potential of the orexin receptor antagonist, suvorexant, compared with zolpidem in a randomized crossover study. Journal of clinical psychopharmacology. 2016;36(4):314-23.
  21. Levy-Cooperman N, McIntyre G, Bonifacio L, McDonnell M, Davenport J, Covington P, et al. Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed μ-and κ-opioid receptor agonist and δ-opioid receptor antagonist. Journal of Pharmacology and Experimental Therapeutics. 2016;359(3):471-81.
  22. Levy-Cooperman N, McIntyre G, Bonifacio L, Davenport J, Covington P, Dove L, et al., editors. Lack of subjective abuse-related effects of oral eluxadoline: a novel mu-delta opiate modulator for oral use in ibs-d. Clinical Pharmacology & Therapeutics; 2016: Wiley-Blackwell 111 River St, Hoboken 07030-5774, NJ USA.
  23. Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, et al. The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting. Clinical Pharmacology & Therapeutics. 2016;100(3):275-86.
  24. Carter L, Wang G, Sellers E, Henningfield J, Lu Y, Kelsh D, et al., editors. Evaluation of the human abuse liability of JZP-110, a wake-promoting agent. Journal Of Sleep Research; 2016: Wiley-Blackwell 111 River St, Hoboken 07030-5774, NJ USA.
  25. Shram MJ, Silverman B, Ehrich E, Sellers EM, Turncliff R. Use of remifentanil in a novel clinical paradigm to characterize onset and duration of opioid blockade by samidorphan, a potent μ-receptor antagonist. Journal of clinical psychopharmacology. 2015;35(3):242.